Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (ARMP)
NYSE MKT:ARMP
RESEARCH TOOLSreports
Armata Pharmaceuticals (ARMP) Stock Price & Analysis
244 Followers
ARMP Stock Chart & Stats
Day’s Range$3.07 - $3.4
52-Week Range― - ―
Previous Close$3.26
Volume4.52K
Average Volume (3M)N/A
Market Cap
$108.83M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Aug 14, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside165.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Armata Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressAP-PA02 in cystic fibrosis reported positive data from its Phase 1b/2a study, suggesting potential for successful future clinical development.
Financial StrategyArmata has secured two non-dilutive partnerships and runs its own proprietary phage specific GMP manufacturing facility, showcasing financial prudence and operational control.
Product DevelopmentArmata's lead product candidate, AP-PA02, targets chronic P. aeruginosa infections in cystic fibrosis patients, indicating a strong potential market.
Bears Say
Earnings DiscrepancyArmata reported 1Q’24 earnings with EPS of -$0.69 versus consensus of -$0.31, indicating financial performance below market expectations.
Financial Instruments ValuationThe discrepancy in Armata's earnings is primarily from the GAAP fair value of convertible debt, suggesting potential volatility in financial instrument valuation.
Yearly Financial PerformanceArmata's 2023 EPS of ($1.91) fell short of the estimated ($1.71), reflecting a concerning trend in the company's yearly financial performance.
---
Ownership Overview
72.38% Insiders
0.92% Mutual Funds
0.58% Other Institutional Investors
26.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Currently, no data Available
What is Armata Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Aug 14, 2024 which is in 96 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.38.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -$0.37.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Currently, no data Available
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went down -3.497%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
---
Armata Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (165.78% Upside)
$8.00 (165.78% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
154.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.64%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
---
ARMP Stock 12 Month Forecast
Average Price Target
$8.00
▲(165.78% Upside)
Technical Analysis
Best Analysts Covering ARMP
1 Year
1 Year Success Rate
11/27 ratings generated profit
1 Year Average Return
-1.81%
reiterated a buy rating 3 days ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 40.74% of your transactions generating a profit, with an average return of -1.81% per trade.
---